title: Nonresponse and Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Treatment.
abstract: To evaluate the surgical outcome of type 1 retinopathy of prematurity (ROP) after intravitreal ranibizumab (IVR) (Lucentis; Genentech, South San Francisco, CA) treatment.
  
  
  
  This was a prospective case series. Premature infants with treatment-requiring ROP who received IVR injections from 2013 to 2015 were included.
  
  
  
  Twenty-two eyes of 12 children were included in the study. Complete resolution of ROP after a single IVR was noted in 73% of eyes. Retreatment was needed in 27% of eyes due to nonresponse to IVR (18%) or recurrence of ROP (9%). After that, all treated eyes (100%) demonstrated regressed ROP with attached retina. The median visual acuity was 0.3 LogMAR (range: 0 LogMAR to 0.8 LogMAR) with a mean follow-up of 25.2 months ± 6.8 months.
  
  
  
  IVR is effective and well-tolerated for patients with treatment-requiring ROP. However, nonresponse to IVR or recurrence of ROP after IVR was noted in 27% of treated eyes and required additional treatment. [Ophthalmic Surg Lasers Imaging Retina. 2016;47:1095-1105.].
authors.forename: Tsengelmaa
authors.initials: T
authors.lastname: Chuluunbat
authors.forename: R V Paul
authors.initials: RV
authors.lastname: Chan
authors.forename: Nan-Kai
authors.initials: NK
authors.lastname: Wang
authors.forename: Reyin
authors.initials: R
authors.lastname: Lien
authors.forename: Yen-Po
authors.initials: YP
authors.lastname: Chen
authors.forename: An-Ning
authors.initials: AN
authors.lastname: Chao
authors.forename: Kuan-Jen
authors.initials: KJ
authors.lastname: Chen
authors.forename: Tun-Lu
authors.initials: TL
authors.lastname: Chen
authors.forename: Yih-Shiou
authors.initials: YS
authors.lastname: Hwang
authors.forename: Chi-Chun
authors.initials: CC
authors.lastname: Lai
authors.forename: Wei-Chi
authors.initials: WC
authors.lastname: Wu
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D005865:Gestational Age; D006801:Humans; D007223:Infant; D058449:Intravitreal Injections; D008297:Male; D011446:Prospective Studies; D000069579:Ranibizumab / Q000008:administration & dosage*; D012008:Recurrence; D012160:Retina / Q000473:pathology; D012178:Retinopathy of Prematurity / Q000175:diagnosis / Q000188:drug therapy*; D019233:Retreatment; D013997:Time Factors; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D000069579:Ranibizumab